ArticleFrontiers in immunology2026
First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunochemotherapy is standard for small-cell lung cancer (SCLC), yet efficacy and safety of serplulimab for patients with brain metastases (BM) remain to be fully elucidated in routine clinical practice. Methods: In this multicenter, prospective cohort study, SCLC patients with BM who received first-line serplulimab plus platinum-based chemotherapy or chemotherapy alone were included. Primary endpoint was intracranial progression-free survival (iPFS). Secondary endpoints included extracranial PFS, systemic PFS, overall survival (OS), tumor response, and safety. Results: A total of 62 patients with SCLC and confirmed BM were included. Patients treated with serplulimab achieved an intracranial objective response rate of 78.57%. With a median follow-up of 22.17 months, serplulimab combined with chemotherapy demonstrated significant benefits across all survival outcomes. The serplulimab group demonstrated significantly prolonged median iPFS (8.93 vs. 6.37 months; log-rank Conclusion: First-line serplulimab plus chemotherapy demonstrates robust intracranial efficacy and survival benefits with manageable safety in SCLC patients with BM. Integrating cranial radiotherapy appears to offer complementary clinical value, supporting this multimodal strategy as a viable therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.